Respiratory Drugs During Breastfeeding

2019 ◽  
Vol 14 (9) ◽  
pp. 613-615
Author(s):  
Philip O. Anderson
Keyword(s):  
1984 ◽  
Vol 7 ◽  
pp. S489
Author(s):  
R. C.W. Hall ◽  
J. H. Coleman ◽  
T. P. Beresford
Keyword(s):  

Author(s):  
Carl Waldmann ◽  
Andrew Rhodes ◽  
Neil Soni ◽  
Jonathan Handy

This chapter discusses respiratory drugs and includes discussion on bronchodilators (describing β‎2-agonists, anticholinergic agents, and xanthine derivatives), nitric oxide (history, biochemistry, clinical use of inhaled nitric oxide, administration of inhaled nitric oxide, adverse effects of inhaled nitric oxide, and adjunctive therapies), mucolytics (properties of mucus, types of mucolytics, clinical applications, and side-effects), and helium–oxygen gas mixtures (including nomenclature, rationale, indications, expected effects, presentation, face mask administration, nebulization, patient monitoring during therapy, stopping helium–oxygen therapy, indications for helium–oxygen mask ventilation, indications for helium–oxygen intermittent positive pressure ventilation (IPPV) via endotracheal or tracheostomy tube, patient monitoring during IPPV therapy, stopping helium–oxygen therapy, and published trials).


2020 ◽  
Vol 6 (4) ◽  
pp. 00479-2020
Author(s):  
Jesper Rømhild Davidsen ◽  
Lars Christian Lund ◽  
Christian B. Laursen ◽  
Jesper Hallas ◽  
Daniel Pilsgaard Henriksen

BackgroundIdiopathic pulmonary fibrosis (IPF) is a well-characterised interstitial lung disease. Typically, IPF diagnosis is delayed due to nonspecific symptoms, but can also be delayed due to treatment attempts on false indication or due to treatment targeting common comorbidities. This observational study aimed to assess the dynamics in the medication and diagnosis patterns in the period before and after an IPF diagnosis.MethodsWe identified all Danish patients with IPF between 2002 and 2017. We evaluated new and ongoing drug treatments and incident diagnoses 36 months before and 12 months after an IPF diagnosis by use of Danish nationwide registries. To aid interpretation, 10 random controls were recruited for each case.ResultsA total of 650 IPF patients were identified (median age 73 years (interquartile range 65–78), 70.3% males). Prior to the IPF diagnosis, the most prevalent diagnoses were dyspnoea and non-IPF interstitial lung diseases. For drug use, IPF patients had higher initiation rates for antibiotics, oral corticosteroids and mucolytics. In terms of drug volume, IPF patients used more respiratory drugs, antibiotics, immunosuppressants, corticosteroids, proton pump inhibitors, benzodiazepines and opium alkaloids within the 6 months preceding their IPF diagnosis, compared to the controls. Overall drug use decreased after an IPF diagnosis, mainly due to a reduced glucocorticoid and cardiovascular drug use.ConclusionAmong IPF patients, an increased drug use was observed for diagnoses with symptoms overlapping those of IPF, particularly this was observed during the last 6 months before an IPF diagnosis. This emphasises the need for an increased IPF awareness.


2019 ◽  
Vol 33 (12) ◽  
Author(s):  
Başak Gökçe ◽  
Nurhan Sarıoğlu ◽  
Nahit Gençer ◽  
Oktay Arslan

2019 ◽  
Vol 103 ◽  
pp. 218-228
Author(s):  
Hyesung Lee ◽  
Inmyung Song ◽  
Sun Mi Shin ◽  
Han Eol Jeong ◽  
Eui-Kyung Lee ◽  
...  

2010 ◽  
Vol 19 (2) ◽  
pp. 148-154 ◽  
Author(s):  
Laurent Laforest ◽  
Francois Denis ◽  
Eric Van Gansea ◽  
Cecile Ritleng ◽  
Christel Saussier ◽  
...  

CHEST Journal ◽  
1981 ◽  
Vol 80 (6) ◽  
pp. 877-880 ◽  
Author(s):  
W. Foster ◽  
E. Langenback ◽  
E. Bergofsky

2017 ◽  
Vol 14 (4) ◽  
pp. 1033-1046 ◽  
Author(s):  
Ayşe Ufuk ◽  
Frauke Assmus ◽  
Laura Francis ◽  
Jonathan Plumb ◽  
Valeriu Damian ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document